Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Matthew Matasar, Zhiming Li, Theodoros P. Vassilakopoulos, Juan-Manuel Sancho, Andreas Viardot, Andrew McMillan, Mehmet Sinan Dal, Juliana Pereira, Jin Seok Kim, Lugui Qiu, Connie Lee Batlevi, Rania Ibrahim, Juana Hernandez, Bruce McCall, Yanwen Jiang, Mark Yan, Will Harris, Lisa Musick, Corinne Haioun

Open source

DOI: 10.1200/jco-25-02849
Published: 2026-09-01
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-02849,
  title = {Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial},
  author = {Matthew Matasar and Zhiming Li and Theodoros P. Vassilakopoulos and Juan-Manuel Sancho and Andreas Viardot and Andrew McMillan and Mehmet Sinan Dal and Juliana Pereira and Jin Seok Kim and Lugui Qiu and Connie Lee Batlevi and Rania Ibrahim and Juana Hernandez and Bruce McCall and Yanwen Jiang and Mark Yan and Will Harris and Lisa Musick and Corinne Haioun},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-02849},
  url = {https://doi.org/10.1200/jco-25-02849}
}

RIS

TY  - JOUR
TI  - Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial
AU  - Matthew Matasar
AU  - Zhiming Li
AU  - Theodoros P. Vassilakopoulos
AU  - Juan-Manuel Sancho
AU  - Andreas Viardot
AU  - Andrew McMillan
AU  - Mehmet Sinan Dal
AU  - Juliana Pereira
AU  - Jin Seok Kim
AU  - Lugui Qiu
AU  - Connie Lee Batlevi
AU  - Rania Ibrahim
AU  - Juana Hernandez
AU  - Bruce McCall
AU  - Yanwen Jiang
AU  - Mark Yan
AU  - Will Harris
AU  - Lisa Musick
AU  - Corinne Haioun
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-02849
UR  - https://doi.org/10.1200/jco-25-02849
ER  -

APA

Matasar, M., Li, Z., Vassilakopoulos, T. P., Sancho, J., Viardot, A., McMillan, A., Dal, M. S., Pereira, J., Kim, J. S., Qiu, L., Batlevi, C. L., Ibrahim, R., Hernandez, J., McCall, B., Jiang, Y., Yan, M., Harris, W., Musick, L., & Haioun, C. (2026). Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02849

Source records

crossref · retrieved 2026-09-26T17:07:00.951Z